CONTRIBUTIONS FROM THE MEMBER SOCIETIES. RE-EVALUATION OF PALIVIZUMAB USAGE IN ISRAEL
The new recommendations of the American Academy References of Pediatrics (AAP) calling for a more limited and narrower 1. Updated guidance for palivizumab prophylaxis among usage of palivzumab (synagis) for the prevention of RSV in infants and young children at increased risk of hospitalihigh risk groups have caused some confusion among pedia- zation for respiratory syncytial virus infection. Pediatrics. tricians in Israel. 2014 Aug;134(2):e620–38. For the last decade several professional associa- 2. Ralston SL et al. Clinical practice guideline: the diagnosis, tions in Israel especially the Neonatology and The Pediatric management, and prevention of bronchiolitis. Pediatrics.
Авторы
Тэги
Тематические рубрики
Предметные рубрики
В этом же номере:
Резюме по документу**
CONTRIBUTIONS FROM THE MEMBER
SOCIETIES
RE-EVALUATION OF PALIVIZUMAB USAGE
IN ISRAEL
The new recommendations of the American Academy
of Pediatrics (AAP) calling for a more limited and narrower
usage of palivzumab (synagis) for the prevention of RSV in
high risk groups have caused some confusion among pediatricians
in Israel. <...> For the last decade several professional associations
in Israel especially the Neonatology and The Pediatric
Pulmonology Associations have advocated for a gradual
expansion of the populations eligible for this expensive
technology. <...> While 14 years ago synagis was recommended
for 200 infants born than 28 weeks and those with
chronic lung diseases, the funding for the prophylaxis was
consistently increased and recently includes all infants
born 34 week + 7 days and included 2750 eligible
infants. <...> In response to this reaction, The Israeli Pediatric As sociation,
has nominated an ad hoc committee that included
the chairmen of the relevant associations and societies
(Neonatology, Pediatric Pulmonology, Pediatric Intensive
Care, Public Health, Pediatric Infectious Diseases, and representative
of the Ministry of Health (MOH). <...> Palivizumab has been proven effective in reducing hospitalizations
following RSV infection at high risk groups.
2. <...> Palivizumab has not been proven to reduce mortality
associated with RSV infection.
3. <...> While palivizumab prophylaxis reduces ICU hospitalizations
due to RSV infections, it was not shown to reduce
mechanical ventilation due to this infection.
4. <...> The cost of prevention of 1 RSV hospitalization is different
among different countries and could be quite high
( 250,000$ in most models).
5. <...> Palivizumab prophylaxis may decrease wheezing episodes
among treated infants.
6. <...> While palivizumab may reduce hospitalizations among
high risk patients its usage is not supposed to significantly
affect the total burden of RSV infection since the overwhelming
part of RSV hospitalization affect otherwise
healthy infants who are not eligible for RSV prophylaxis. <...> To continue during the present winter (2014–2015 season)
with the same criteria.
2. <...> To establish immediately following the present winter a
cost benefit analysis in order to determine whether the
current criteria are cost effective. <...> The analysis is supposed
to be finished prior to the next season in order to
define more correctly the population that is eligible <...>
** - вычисляется автоматически, возможны погрешности
Похожие документы: